Találati lista | Tudóstér

001-es BibID:	BIBFORM108875
035-os BibID:	(cikkazonosító)4115
Első szerző:	Lőrincz Hajnalka (biológus)
Cím:	Impaired Organokine Regulation in Non-Diabetic Obese Subjects : halfway to the Cardiometabolic Danger Zone / Hajnalka Lőrincz, Balázs Ratku, Sára Csiha, Ildikó Seres, Zoltán Szabó, György Paragh, Mariann Harangi, Sándor Somodi
Dátum:	2023
ISSN:	1422-0067
Megjegyzések:	Altered organokine expression contributes to increased cardiometabolic risk in obesity. Our aim was to evaluate the associations of serum afamin with glucose homeostasis, atherogenic dyslipidemia, and other adipokines in severe obesity to clarify the early metabolic alterations. 106 non diabetic obese (NDO) subjects and 62 obese patients with type 2 diabetes matched for age, gender, and body mass index (BMI) were enrolled in this study. We compared their data with 49 healthy, lean controls. Serum afamin and retinol-binding protein 4 (RBP4), as well as plasma plasminogen activator inhibitor-1 (PAI-1), were measured with ELISA, and lipoprotein subfractions were analyzed using Lipoprint gel electrophoresis. Afamin and PAI-1 found to be significantly higher in the NDO and T2M group (p < 0.001 and p < 0.001, respectively) than in the controls. In contrast, RBP4 was unexpectedly lower in the NDO and T2DM group compared to controls (p < 0.001). Afamin showed negative correlations with mean LDL size and RBP4, but positive correlations with anthropometric, glucose/lipid parameters, and PAI-1 in both the overall patients and the in NDO + T2DM groups. BMI, glucose, intermediate HDL, and small HDL were predictors of afamin. Afamin may serve as a biomarker for the severity of cardiometabolic disturbances in obesity. The complexity of organokine patterns in NDO subjects draws attention to the diverse spectrum of obesity-related comorbidities.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk obesity type 2 diabetes insulin resistance afamin plasminogen-activator inhibitor-1 retinol binding protein 4 lipid metabolism lipoprotein subfraction cardiometabolic
Megjelenés:	International Journal Of Molecular Sciences. - 24 : 4 (2023), p. 1-13. -
További szerzők:	Ratku Balázs (1985-) (mentőtiszt) Csiha Sára (1985-) (Biológus) Seres Ildikó (1954-) (biokémikus) Szabó Zoltán (1973-) (belgyógyász, kardiológus) Paragh György (1953-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Somodi Sándor (1977-) (belgyógyász)
Pályázati támogatás:	PD124126 OTKA K142273 OTKA
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM108726
035-os BibID:	(cikkazonosító)270
Első szerző:	Lőrincz Hajnalka (biológus)
Cím:	Crucial Regulatory Role of Organokines in Relation to Metabolic Changes in Non-Diabetic Obesity / Lőrincz Hajnalka, Somodi Sándor, Ratku Balázs, Harangi Mariann, Paragh György
Dátum:	2023
ISSN:	2218-1989
Megjegyzések:	Obesity is characterized by an excessive accumulation of fat leading to a plethora of medical complications, including coronary artery disease, hypertension, type 2 diabetes mellitus or impaired glucose tolerance and dyslipidemia. Formerly, several physiological roles of organokines, including adipokines, hepatokines, myokines and gut hormones have been described in obesity, especially in the regulation of glucose and lipid metabolism, insulin sensitivity, oxidative stress, and low-grade inflammation. The canonical effect of these biologically active peptides and proteins may serve as an intermediate regulatory level that connects the central nervous system and the endocrine, autocrine, and paracrine actions of organs responsible for metabolic and inflammatory processes. Better understanding of the function of this delicately tuned network may provide an explanation for the wide range of obesity phenotypes with remarkable inter-individual differences regarding comorbidities and therapeutic responses. The aim of this review is to demonstrate the role of organokines in the lipid and glucose metabolism focusing on the obese non-diabetic subgroup. We also discuss the latest findings about sarcopenic obesity, which has recently become one of the most relevant metabolic disturbances in the aging population.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk metabolically healthy obesity non-diabetic obesity adipokine hepatokine myokine sarcopenic obesity prediabetes insulin resistance cardiovascular risk
Megjelenés:	Metabolites. - 13 : 2 (2023), p. 1-27. -
További szerzők:	Somodi Sándor (1977-) (belgyógyász) Ratku Balázs (1985-) (mentőtiszt) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Paragh György (1953-) (belgyógyász)
Pályázati támogatás:	OTKA K142273 Egyéb OTKA PD124126 Egyéb
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM103904
Első szerző:	Lőrincz Hajnalka (biológus)
Cím:	Plasminogen activator inhibitor-1 level associated with the components of metabolic syndrome in a 4G/5G polymorphism dependent manner / Lőrincz H., Galgóczy E., Katkó M., Ratku B., Ötvös T., Harangi M., Paragh G., Szabó Z., Somodi S.
Dátum:	2022
ISSN:	0021-9150
Megjegyzések:	Background and Aims : The elevated level of plasminogen activator inhibitor- 1 (PAI-1) in obese subjects with metabolic syndrome and in patients with type 2 diabetes is well established. A common 4G/5G single guanine insertion/deletion polymorphism in the promoter region of the PAI-1 gene is of functional importance in regulating PAI-1 expression. We aimed to study the potential different correlations of carbohydrate and lipid parameters and plasma PAI-1 levels in the 4G and 5G carriers in obese and lean subjects. Methods: Ninety-three morbid obese and thirty-two lean non-diabetic participants were enrolled. PAI-1 4G/5G polymorphism was determined with allele-specific PCR. Plasma PAI-1 levels were measured by ELISA. Results: The genotype distribution of PAI-1 4G/5G polymorphism was not significantly differed in obese patients (4G/4G 27.9%; 4G/5G 45.2% and 5G/ 5G 26.9%) compared to controls (4G/4G 31.3%; 4G/5G 46.9% and 5G/5G 21.9%, p?0.8). Slightly higher PAI-1 levels were found in 4G carriers (4G/ 4G+4G/5G) in obese and control group (p?0.07 and p?0.02, respectively). In all subjects with 4G/5G genotype, plasma PAI-1 correlated negatively with high-density lipoprotein-cholesterol (HDL-C) (p?0.02) and apolipoprotein AI (apoAI) levels (p<0.001). In 5G/5G participants, PAI-1 also correlated negatively with HDL-C (p?0.025) and apoAI (p?0.007) concentrations, moreover positively with triglyceride (p?0.02), fasting glucose (p?0.002) and haemoglobin A1c (p?0.027). These correlations are lacking in 4G/4G participants. Conclusions: The observed correlations between PAI-1 levels and the components of metabolic syndrome suggest a closer link between PAI-1 and lipid and carbohydrate metabolism in subjects with 5G/5G genotype. This presentation was supported by the Bridging Fund (Faculty of Medicine, University of Debrecen) and PD124126 project.
Tárgyszavak:	Orvostudományok Egészségtudományok idézhető absztrakt folyóiratcikk atherosclerosis Plasminogen activator inhibitor-1 promoter polymorphism obesity lipid metabolism lipoprotein
Megjelenés:	Atherosclerosis. - 355 (2022), p. e248. -
További szerzők:	Galgóczi Erika (1986-) (biológus) Katkó Mónika (1980-) (biológus) Ratku Balázs (1985-) (mentőtiszt) Ötvös Tamás (1980-) (orvos) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Paragh György (1953-) (belgyógyász) Szabó Zoltán (1973-) (belgyógyász, kardiológus) Somodi Sándor (1977-) (belgyógyász)
Pályázati támogatás:	PD124126 Egyéb
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: